EUCTR2006-005174-42-NL进行中（未招募）1 期
Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab maintenance in patients with diffuse large B-cell lymphoma - HOVON 84 NH
HOVON Foundation0 个研究点目标入组 600 人开始时间: 2007年2月14日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •For first randomization:
- •- Patients with a confirmed histologic diagnosis of diffuse large B-cell lymphoma (DLBCL) based upon a representative histology specimen according to the WHO classification (see appendix A)
- •- DLBCL must be CD20 positive
- •- Ann Arbor stages II-IV (see appendix C)
- •- Age 18-65 years and age-adjusted IPI 1-3 OR age 66-80 years and age-adjusted IPI 0-3
- •- WHO performance status 0 – 2 (see appendix E)
- •- Written informed consent
- •For second randomization:
- •Patients achieving a CR (or FDG-PET negative PR/CRu) after 6 (elderly) or 8 (young patients) cycles of R-CHOP14 will be randomized to maintenance treatment with rituximab or no further treatment.
- •- Patients in complete remission or FDG-PET negative partial remission/unconfirmed complete remission at least 4 weeks after the last cycle of R-CHOP14 (including last rituximab administration)
- •- Time interval since last cycle of R-CHOP14 (including last rituximab administration) between 4 and 8 weeks
- •- No rituximab-related adverse event necessitating stopping of rituximab administration
- •- No active infection
- •- Written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 300
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 300
排除标准
- •-Age 18-65 (inclusive) years and aa-IPI 0 (no risk factors)
- •-Intolerance of exogenous protein administration
- •-Severe cardiac dysfunction (NYHA classification III-IV, see appendix F) or LVEF < 45%
- •- Congestive heart failure or symptomatic coronary artery disease or cardiac arrhythmias not well controlled with medication. Myocardial infarction during the last 6 months
- •- Severe pulmonary dysfunction (vital capacity or diffusion capacity < 50% of predicted value) unless clearly related to NHL involvement
- •- Patients with uncontrolled asthma or allergy, requiring systemic steroid treatment
- •- Significant hepatic dysfunction (total bilirubin >= 30mmol/l or transaminases >= 2.5 x upper normal limit), unless related to NHL
- •- Significant renal dysfunction (serum creatinine >= 150 umol/l or clearance <= 60 ml/min), unless related to NHL
- •- Clinical signs of severe cerebral dysfunction
- •- Suspected or documented Central Nervous System involvement by NHL
- •- Patients with a history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant and adversely affecting compliance to study drugs
- •- Testicular DLBCL
- •- Primary mediastinal B cell lymphoma
- •- Transformed indolent lymphoma
- •- (EBV) post-transplant lymphoproliferative disorder
- •- Secondary lymphoma after previous chemotherapy or radiotherapy
- •- Major surgery, other than diagnostic surgery, within the last 4 weeks
- •- Patients with active uncontrolled infections
- •- Patients known to be HIV-positive
- •- Active chronic hepatitis B or C infection
- •- Serious underlying medical conditions, which could impair the ability of the patient to participate in the trial (e.g. ongoing infection, uncontrolled diabetes mellitus, gastric ulcers, active autoimmune disease)
- •- Life expectancy < 6 months
- •- Prior treatment with chemotherapy, radiotherapy or immunotherapy for this lymphoma, except a short course of prednisone (< 1 week) and/or cyclophosphamide (< 1 week and not in excess of 900 mg/m2 cumulative) or local radiotherapy in order to control life threatening tumor related symptoms
- •- History of active cancer during the past 5 years, except basal carcinoma of the skin or stage 0 cervical carcinoma
研究者
相似试验
已完成
3 期
Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab maintenance in patients with diffuse large B-cell lymphomalymphomaNL-OMON47490HOVO460
进行中（未招募）
1 期
Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab maintenance in patients with diffuse large B-cell lymphomaMedDRA version: 21.0 Level: LLT Classification code 10012820 Term: Diffuse large B-cell lymphoma NOS System Organ Class: 100000004864diffuse large B-cell lymphomaEUCTR2006-005174-42-BEHOVON Foundation600
尚未招募
不适用
Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab maintenance in elderly patients (66-80 years) with diffuse large B-cell lymphomaDiffuse large B-cell lymphomaNL-OMON23148Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) P/a HOVON Data CenterErasmus MC - Daniel den HoedPostbus 52013008 AE RotterdamTel: 010 4391568Fax: 010 4391028e-mail: hdc@erasmusmc.nl550
进行中（未招募）
1 期
Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab maintenance in elderly patients (66-80 years) with diffuse large B-cell lymphoma - HOVON 84 NHEUCTR2006-005174-42-DKHOVON Foundation550
已完成
不适用
A randomised controlled trial of effects of early life exposure to general anaesthesia on neurobehavioural outcomes in children with cystic fibrosis (CF)Early life exposure to general anaesthesiaNeurobehavioural outcomesAnaesthesiology - AnaestheticsHuman Genetics and Inherited Disorders - Cystic fibrosisCystic FibrosisACTRN12613000057785Department of Health and Ageing132